Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142030 | 1.00 | L3MBTL1 (0.49) | L3MBTL1GAAALDH1A1KDM4EKMT2A | |
| SCHEMBL17609898 | 0.89 | L3MBTL1 (0.41) | L3MBTL1GAAALDH1A1KDM4EKMT2A | |
| SCHEMBL13712 | 0.84 | GAA (0.55) | GAAALDH1A1KDM4EMAPTEPHX2 | |
| SCHEMBL31389658 | 0.84 | L3MBTL1 (0.47) | L3MBTL1GAAALDH1A1KDM4EKMT2A | |
| SCHEMBL30140662 | 0.80 | GAA (0.51) | GAAALDH1A1EPHX2ATRANO1 | |
| SCHEMBL2095941 | 0.77 | GAA (0.55) | GAAEPHX2ATRANO1NAMPT | |
| SCHEMBL2095943 | 0.77 | GAA (0.55) | GAAEPHX2ATRANO1NAMPT | |
| SCHEMBL5643498 | 0.77 | GAA (0.55) | GAAALDH1A1KMT2AEPHX2ATR | |
| SCHEMBL29654196 | 0.77 | ALDH1A1 (0.64) | GAAALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1396138 | 0.77 | ALDH1A1 (0.64) | GAAALDH1A1KDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636815-B | Preparation method and application of pomalidomide connected urea compound | 新乡学院 | 2023-10-27 | — | — | CN | disclosed |
| EP-3894511-B1 | THE PROCESS FOR OBTAINING OF FLUORALKYLATED CARBON QUANTUM DOTS | NOVACIUM (FR) | 2023-06-07 | — | — | EP | disclosed |
| US-20220041924-A1 | THE PROCESS FOR OBTAINING OF FLUORALKYLATED CARBON QUANTUM DOTS | NOVACIUM (FR) | 2022-02-10 | — | — | US | disclosed |
| EP-3894511-A1 | THE PROCESS FOR OBTAINING OF FLUORALKYLATED CARBON QUANTUM DOTS | Zaderko, Alexander (UA) | 2021-10-20 | — | — | EP | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| WO-2020121119-A1 | THE PROCESS FOR OBTAINING OF FLUORALKYLATED CARBON QUANTUM DOTS | ZADERKO ALEXANDER (UA) | 2020-06-18 | — | — | WO | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-9862730-B2 | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| CN-104540835-B | The imidazo thiadiazoles derivative as proteinase activated receptors 4 (PAR4) inhibitor for treating platelet aggregation | 百时美施贵宝公司 | 2017-08-08 | — | — | CN | disclosed |
| EP-2847200-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-09-11 | — | — | US | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20120302562-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012162468-A1 | THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162468-A1 | THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | L3MBTL1 3527/4885GAA 4853/4885ALDH1A1 1853/4885 |
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, CES1, ACHE | L3MBTL1 1281/4885GAA 94/4885ALDH1A1 1022/4885 |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | AR, NR3C2, NR5A1 | L3MBTL1 3527/4885GAA 4853/4885ALDH1A1 1853/4885 |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | MMP13, MMP8, MMP11 | L3MBTL1 2035/4885GAA 233/4885ALDH1A1 1395/4885 |
| US-20120302562-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, CES1, ACHE | L3MBTL1 1281/4885GAA 94/4885ALDH1A1 1022/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | L3MBTL1 3309/4885GAA 266/4885ALDH1A1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.